Data / Drug companies / Bausch & Lomb Incorporated
Bausch & Lomb Incorporated: 85 products in the FDA NDC directory, labeler code 24208
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Bausch & Lomb Incorporated (labeler code 24208) lists 85 products in the FDA National Drug Code Directory, covering 61 finished drugs by generic name. By type: 65 prescription drugs, 20 over the counter drugs. Its main marketing category is generic drugs (ANDA). The newest product started marketing on March 19, 2026.
The request: Watch Bausch & Lomb Incorporated (FDA labeler code 24208): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 24208
- Products in commercial distribution
- 85
- Packages
- 162
- Finished drugs by generic name
- 61
- Prescription products
- 65
- Over the counter products
- 20
- Flagged as original packager
- 84 of 84 products that carry the flag
- Started marketing in the last 12 months
- 1
- Products with a marketing end date set
- 1
- Earliest marketing start
- September 30, 1990
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Generic drugs (ANDA) | 40 | 47.1% |
| New drug applications (NDA) | 31 | 36.5% |
| Over the counter monograph drugs | 12 | 14.1% |
| Authorized generics (NDA) | 1 | 1.2% |
| Other unapproved drugs | 1 | 1.2% |
Products by type
| Type | Products | Share |
|---|---|---|
| Prescription drugs | 65 | 76.5% |
| Over the counter drugs | 20 | 23.5% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Solution/ drops | 40 | 47.1% |
| Solution | 17 | 20% |
| Ointment | 9 | 10.6% |
| Suspension/ drops | 7 | 8.2% |
| Gel | 3 | 3.5% |
| Spray, metered | 2 | 2.4% |
| Tablet | 2 | 2.4% |
| Kit | 1 | 1.2% |
| Injection, suspension | 1 | 1.2% |
| Injection, powder, lyophilized, for solution | 1 | 1.2% |
| Lotion | 1 | 1.2% |
| Suspension | 1 | 1.2% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Opcon-A | 24208-431 | Solution/ drops | New drug applications (NDA) | March 19, 2026 |
| Olopatadine hydrochloride | 24208-967 | Solution | Generic drugs (ANDA) | January 20, 2025 |
| Olopatadine hydrochloride | 24208-617 | Solution | Generic drugs (ANDA) | January 20, 2025 |
| Lumify preservative free eye drops | 24208-538 | Solution/ drops | New drug applications (NDA) | January 1, 2025 |
| Olopatadine Hydrochloride Ophthalmic Solution | 24208-966 | Solution | Generic drugs (ANDA) | December 2, 2024 |
| Xiidra | 24208-911 | Solution/ drops | New drug applications (NDA) | January 2, 2024 |
| Miebo | 24208-377 | Solution | New drug applications (NDA) | May 18, 2023 |
| Tetracaine Hydrochloride | 24208-092 | Solution/ drops | New drug applications (NDA) | September 23, 2022 |
| Atropine Sulfate | 24208-965 | Solution | New drug applications (NDA) | July 13, 2022 |
| Brinzolamide | 24208-464 | Suspension/ drops | Generic drugs (ANDA) | March 31, 2022 |
| Timoptic in Ocudose | 24208-499 | Solution | New drug applications (NDA) | February 17, 2022 |
| Timoptic in Ocudose | 24208-498 | Solution | New drug applications (NDA) | February 17, 2022 |
| Xipere | 24208-040 | Injection, suspension | New drug applications (NDA) | December 17, 2021 |
| Bepotastine Besilate | 24208-630 | Solution/ drops | Authorized generics (NDA) | May 28, 2021 |
| Biotrue Hydration Boost | 24208-006 | Solution/ drops | Over the counter monograph drugs | April 30, 2021 |
| Methazolamide | 24208-023 | Tablet | Generic drugs (ANDA) | October 2, 2020 |
| Methazolamide | 24208-022 | Tablet | Generic drugs (ANDA) | October 2, 2020 |
| Fluorescein Sodium and Benoxinate Hydrochloride | 24208-734 | Solution/ drops | New drug applications (NDA) | March 20, 2020 |
| Lotemax SM | 24208-507 | Gel | New drug applications (NDA) | February 25, 2019 |
| Soothe XP Preservative Free | 24208-742 | Solution/ drops | Over the counter monograph drugs | April 18, 2018 |
| LUMIFY Redness Reliever Eye Drops | 24208-537 | Solution/ drops | New drug applications (NDA) | December 22, 2017 |
| Vyzulta | 24208-504 | Solution/ drops | New drug applications (NDA) | November 2, 2017 |
| Advanced Eye Relief Eye Wash | 24208-005 | Solution/ drops | Over the counter monograph drugs | February 2, 2017 |
| Timoptic | 24208-813 | Solution | New drug applications (NDA) | December 30, 2016 |
| Timoptic | 24208-812 | Solution | New drug applications (NDA) | December 30, 2016 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.